Home Companies Catalysts Deep Dives
Aimovig erenumab APPROVED
Drug Profile
ModalityAntibody
RouteSC
Therapy AreaNeurology
Launch2018-05-17
US LOE2029-05-17
Peak Sales Est$600M
Formulations[{"id":"aimovig-sc","doses":"70mg, 140mg","route":"SC","device":"Autoinjector","setting":"PATIENT_SE
Companies
AMGN (CO_DEVELOPER)50%
NVS (CO_DEVELOPER)50%
Mechanism: CGRP receptor antagonist
Expert: Monoclonal antibody targeting calcitonin gene-related peptide receptor
Everyday: Blocks a protein involved in migraine pain
Targets: ["CGRP"]
Revenue History
PeriodRevenue ($M)
2024$480M
2025$520M
Programs (1)
IndicationStageKey StudyRegional Status
Migraine preventionAPPROVEDSTRIVE/ARISE[{"stage":"APPROVED","region":"US","approval_date":"2018-05-17"},{"stage":"APPRO
Notes
CGRP inhibitor for migraine prevention. Partnered with Amgen.
Data from Supabase · Updated 2026-03-24